• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Cancidas

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Cancidas

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Cancidas is the first in a new class of antifungals, called echinocandins, to be introduced in more than a decade. This medication is approved for the intravenous treatment of invasive aspergillosis in patients who have not responded to standard antifungal therapies.

    Aspergillosis is a life-threatening fungal infection most commonly seen in cancer patients, organ and bone marrow transplant recipients, and HIV/AIDS patients. It affects the lungs and can spread through the bloodstream to other parts of the body. Mortality rates in those with severe aspergillosis range from 50 to 90 percent.

    Clinical Results

    The effectiveness of Cancidas was assessed in a small, multi-center, open-label, non-comparative study involving 69 patients with invasive aspergillosis. Patients were between the ages of 18 and 80 and had been intolerant to other antifungal therapies.

    A favorable response to Cancidas treatment was defined as either complete response or clinically meaningful improvement and was determined by an independent expert panel. The panel determined that 41% of patients who received at least one dose of Cancidas elicited a favorable response and those receiving more than seven days of treatment had a 50% favorable response rate.

    Side Effects

    Adverse events associated with the use of caspofungin acetate may include (but are not limited to) the following:

    •  
    • rash
    • facial swelling
    • itching
    • sensation of warmth

    Mechanism of Action

    Cancidas (caspofungin acetate) is a glucan synthesis inhibitor. Glucan is an essential component of the cell wall of susceptible filamentous fungi, such as Aspergillus fumigatus, the fungus responsible for aspergillosis infection.

    Additional Information

    For additional information on Cancidas, please visit Cancidas.

    Approval Date: 2001-01-01
    Company Name: Merck
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing